肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

新型抗肿瘤药物临床应用指导原则（2021年版）

2021-12-27 中华人民共和国国家卫生健康委员会 国家卫生健康委

抗肿瘤药物合理用药

我委组织国家卫生健康委合理用药专家委员会牵头对《新型抗肿瘤药物临床应用指导原则（2020年版）》进行修改完善，制定了《新型抗肿瘤药物临床应用指导原则（2021年版）》。

中文标题：

新型抗肿瘤药物临床应用指导原则（2021年版）

发布机构：

中华人民共和国国家卫生健康委员会

发布日期：

2021-12-27

简要介绍：

为进一步规范新型抗肿瘤药物临床应用，我委组织国家卫生健康委合理用药专家委员会牵头对《新型抗肿瘤药物临床应用指导原则（2020年版）》进行修改完善，制定了《新型抗肿瘤药物临床应用指导原则（2021年版）》（可在国家卫生健康委网站“医政医管”栏目下载）。现印发你们，请认真组织学习，并贯彻执行。

相关资料下载：
[AttachmentFileName(sort=1, fileName=新型抗肿瘤药物临床应用指导原则.docx)] GetToolGuiderByIdResponse(projectId=1, id=d6c891c00230a65a, title=新型抗肿瘤药物临床应用指导原则（2021年版）, enTitle=, guiderFrom=国家卫生健康委, authorId=0, author=, summary=我委组织国家卫生健康委合理用药专家委员会牵头对《新型抗肿瘤药物临床应用指导原则（2020年版）》进行修改完善，制定了《新型抗肿瘤药物临床应用指导原则（2021年版）》。, cover=https://img.medsci.cn/20211228/1640657856679_5579292.jpg, journalId=0, articlesId=null, associationId=1653, associationName=中华人民共和国国家卫生健康委员会, associationIntro=, copyright=0, guiderPublishedTime=Mon Dec 27 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #484848;">为进一步规范新型抗肿瘤药物临床应用，我委组织国家卫生健康委合理用药专家委员会牵头对《新型抗肿瘤药物临床应用指导原则（2020年版）》进行修改完善，制定了《新型抗肿瘤药物临床应用指导原则（2021年版）》（可在国家卫生健康委网站&ldquo;医政医管&rdquo;栏目下载）。现印发你们，请认真组织学习，并贯彻执行。</span></p>, tagList=[TagDto(tagId=117004, tagName=抗肿瘤药物合理用药)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=117004, guiderKeyword=抗肿瘤药物合理用药, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2167, appHits=70, showAppHits=0, pcHits=697, showPcHits=2095, likes=1, shares=11, comments=9, approvalStatus=1, publishedTime=Tue Dec 28 10:14:19 CST 2021, publishedTimeString=2021-12-27, pcVisible=1, appVisible=1, editorId=92910, editor=rayms, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Tue Dec 28 10:23:40 CST 2021, updatedBy=92910, updatedName=rayms, updatedTime=Sat Jan 06 18:31:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=新型抗肿瘤药物临床应用指导原则.docx)])
新型抗肿瘤药物临床应用指导原则.docx
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1186251, encodeId=f37d1186251a6, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7b91716272, createdName=DDmarine, createdTime=Thu Jan 20 01:42:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185277, encodeId=ff9311852e76b, content=好东西！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/08/7dbdeedf97a14b6d34bcf8e67f312aa2.jpg, createdBy=72c12193044, createdName=嗯哪, createdTime=Mon Jan 17 18:55:45 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179585, encodeId=147211e958591, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:03 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179584, encodeId=2c6911e9584ac, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:02 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179583, encodeId=55ed11e95836a, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:00 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-01-20 DDmarine

    好东西，谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1186251, encodeId=f37d1186251a6, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7b91716272, createdName=DDmarine, createdTime=Thu Jan 20 01:42:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185277, encodeId=ff9311852e76b, content=好东西！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/08/7dbdeedf97a14b6d34bcf8e67f312aa2.jpg, createdBy=72c12193044, createdName=嗯哪, createdTime=Mon Jan 17 18:55:45 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179585, encodeId=147211e958591, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:03 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179584, encodeId=2c6911e9584ac, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:02 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179583, encodeId=55ed11e95836a, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:00 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-01-17 嗯哪

    好东西！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1186251, encodeId=f37d1186251a6, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7b91716272, createdName=DDmarine, createdTime=Thu Jan 20 01:42:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185277, encodeId=ff9311852e76b, content=好东西！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/08/7dbdeedf97a14b6d34bcf8e67f312aa2.jpg, createdBy=72c12193044, createdName=嗯哪, createdTime=Mon Jan 17 18:55:45 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179585, encodeId=147211e958591, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:03 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179584, encodeId=2c6911e9584ac, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:02 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179583, encodeId=55ed11e95836a, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:00 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-01-01 一己怀

    好东西，谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1186251, encodeId=f37d1186251a6, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7b91716272, createdName=DDmarine, createdTime=Thu Jan 20 01:42:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185277, encodeId=ff9311852e76b, content=好东西！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/08/7dbdeedf97a14b6d34bcf8e67f312aa2.jpg, createdBy=72c12193044, createdName=嗯哪, createdTime=Mon Jan 17 18:55:45 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179585, encodeId=147211e958591, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:03 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179584, encodeId=2c6911e9584ac, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:02 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179583, encodeId=55ed11e95836a, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:00 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-01-01 一己怀

    好东西，谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1186251, encodeId=f37d1186251a6, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f7b91716272, createdName=DDmarine, createdTime=Thu Jan 20 01:42:05 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185277, encodeId=ff9311852e76b, content=好东西！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/08/7dbdeedf97a14b6d34bcf8e67f312aa2.jpg, createdBy=72c12193044, createdName=嗯哪, createdTime=Mon Jan 17 18:55:45 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179585, encodeId=147211e958591, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:03 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179584, encodeId=2c6911e9584ac, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:02 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179583, encodeId=55ed11e95836a, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:00 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-01-01 一己怀

    好东西，谢谢

    0